FDA okays Teva prostate cancer drug

Mitoxantrone Hydrochloride injection USP is used in combination with corticosteroids.

April 14, 2006 00:08
1 minute read.
teva logo 88

teva logo 88. (photo credit: )


Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analysis from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For $5 a month you will receive access to the following:

  • A user experience almost completely free of ads
  • Access to our Premium Section
  • Content from the award-winning Jerusalem Report and our monthly magazine to learn Hebrew - Ivrit
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief


Teva Pharmaceutical Industries Ltd. announced said late Wednesday that the US Food and Drug Administration has granted final approval for the company's generic drug treatment for patients with prostate cancer. Mitoxantrone Hydrochloride injection USP, is used in combination with corticosteroids as an initial treatment for patients in pain from advanced hormone-refractory prostate cancer. It can also be used in combination with other products for the initial therapy for acute nonlymphocytic leukemia in adults. Teva said it will immediately begin shipping the drug, which is the AP-rated equivalent of Serono's Novantrone Injection. Separately, Teva said it expected to receive market exclusivity over the generic version of Pravachol, a cholesterol-lowering drug, next week after the FDA denied exclusivity to Canada's largest pharmaceuticals company Apotex, which requested 180-day exclusivity for pravastatin, the active ingredient in Pravachol. In October 2005, the US District Court granted Teva's request to prevent the FDA administration from approving competing generic drug maker ANDA's generic Pravastatin Sodium Tablets 10 mg., 20 mg. and 40 mg., until the expiration of Teva's 180-day exclusivity. The FDA concluded that it "interprets the court decision trigger provision to require a decision of a court that on its face evidences a holding on the merits of patent non-infringement, invalidity, or unenforceability. The July 23, 2004 Apotex-Bristol dismissal does not contain such a holding." Teva expects final approval with exclusivity on April 20, when the product patent held by Bristol-Myers Squibb expires. Bristol-Myers' sales of Pravachol amounted to $2.6 billion. in 2004.

Join Jerusalem Post Premium Plus now for just $5 and upgrade your experience with an ads-free website and exclusive content. Click here>>

Related Content

The Teva Pharmaceutical Industries
April 30, 2015
Teva doubles down on Mylan, despite rejection


Cookie Settings